Abstract
High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 1327-1337 |
| Number of pages | 11 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 13 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- extranodal lymphoma
- neurotoxicity
- radiotherapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
Current uses of radiation therapy in patients with primary CNS lymphoma. / Citterio, Giovanni; María Ferreri, Andrés José; Reni, Michele.
In: Expert Review of Anticancer Therapy, Vol. 13, No. 11, 2013, p. 1327-1337.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current uses of radiation therapy in patients with primary CNS lymphoma
AU - Citterio, Giovanni
AU - María Ferreri, Andrés José
AU - Reni, Michele
PY - 2013
Y1 - 2013
N2 - High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.
AB - High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.
KW - extranodal lymphoma
KW - neurotoxicity
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84887281432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887281432&partnerID=8YFLogxK
U2 - 10.1586/14737140.2013.851007
DO - 10.1586/14737140.2013.851007
M3 - Article
VL - 13
SP - 1327
EP - 1337
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 11
ER -